Abstract
The expression of CYP27B1 or vitamin D 1α-hydroxylase (1α-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1α,25-dihydroxyvitamin D [1α,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues.
Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression.
In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa.
The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa.
Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.
Keywords: Vitamin D3, 24-hydroxylase, splicing variants, MCF-7, MCF-10, breast tissue.
Anti-Cancer Agents in Medicinal Chemistry
Title:Implication of CYP24A1 Splicing in Breast Cancer
Volume: 14 Issue: 1
Author(s): Chimi Scheible, Marc Thill, Sascha Baum, Erich Solomayer and Michael Friedrich
Affiliation:
Keywords: Vitamin D3, 24-hydroxylase, splicing variants, MCF-7, MCF-10, breast tissue.
Abstract: The expression of CYP27B1 or vitamin D 1α-hydroxylase (1α-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1α,25-dihydroxyvitamin D [1α,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues.
Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression.
In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa.
The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa.
Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.
Export Options
About this article
Cite this article as:
Scheible Chimi, Thill Marc, Baum Sascha, Solomayer Erich and Friedrich Michael, Implication of CYP24A1 Splicing in Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/18715206113139990311
DOI https://dx.doi.org/10.2174/18715206113139990311 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology A Review on Synthetic and Natural Steroid Dimers: 1997-2006
Current Medicinal Chemistry Synthetic Sphingosine 1-Phosphate Receptor Modulators - Opportunities and Potential Pitfalls
Current Topics in Medicinal Chemistry An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Palladium (II) Complex Enhances ROS-Dependent Apoptotic Effects <i>via</i> Autophagy Inhibition and Disruption of Multiple Signaling Pathways in Colorectal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting DNA Topoisomerase I with Non-Camptothecin Poisons
Current Medicinal Chemistry Current Management of Neonatal Neuroblastoma
Current Pediatric Reviews Chalcones in Cancer: Understanding their Role in Terms of QSAR
Current Medicinal Chemistry New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry Regulation of Ion Channels, Cellular Carriers and Na(+)/K(+)/ATPase by Janus Kinase 3
Current Medicinal Chemistry Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making
Current Pharmaceutical Biotechnology Mechanism of Action of Limonene in Tumor Cells: A Systematic Review and Meta-Analysis
Current Pharmaceutical Design Genetic Variation in the β2-Adrenergic Receptor: Impact on Intermediate Cardiovascular Phenotypes
Current Pharmacogenomics and Personalized Medicine Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets Nanocarriers for Gene Delivery - Polymer Structure, Targeting Ligands and Controlled-Release Devices
Current Nanoscience The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
Letters in Drug Design & Discovery Modulation of the Endocannabinoid System by Lipid Rafts
Current Medicinal Chemistry